Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0007095 (
carcinoid
)
6,990
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interferon alpha (IFN-alpha) has been shown to produce antitumor effects in 50-80% of
carcinoid
tumor patients and has demonstrated anti-proliferative effects in
carcinoid
tumor cells, but the mechanism is not well established. This study presents evidence that in a
carcinoid
tumor cell line, Bon1, IFN-alpha increases the expression of p21 and promotes nuclear translocation of endogenous p21. Furthermore, immunoprecipitation experiments demonstrated that p21 formed immuno-complexes with Stat1 and Stat2 in the nucleus of cells. Interferon alpha can decrease G1- and G2-phase cells, but increase S-phase population. The p21 mRNA expression is inversely correlated to the G1 population (r = -0.933, P < 0.05) and positively correlated to the S-phase population (r = 0.901, P < 0.05). In addition, IFN-alpha inhibited cyclin dependent kinases (CDK), CDK2-,
CDK3
-, CDK4-, and cyclin E- but not cyclin A-associated kinase activities. Immunodepletion of p21 resulted in a significant enhancement of
CDK3
kinase activity (approximately 1.6-fold increase). These results suggest that the mechanism of antitumor and cell cycle regulation of IFN-alpha in
carcinoid
tumors may, at least in part, be p21-dependent. Based on these results, we conclude that IFN-alpha exerts antitumor effects by increased p21 expression in neuroendocrine tumors.
...
PMID:Effects of interferon alpha on the expression of p21cip1/waf1 and cell cycle distribution in carcinoid tumors. 1202 30